Evidence map›Paper›PMID 39478018›Full record

ArticleNature communications2024

Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer.

Yohann Loriot, Maud Kamal, Laurene Syx, Remy Nicolle, Celia Dupain, Naoual Menssouri, Igor Duquesne, Pernelle Lavaud, Claudio Nicotra, Maud Ngocamus and 21 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Yohann Loriot *Gustave Roussy, DITEP, Gustave Roussy, Villejuif, France. yohann.loriot@gustaveroussy.fr.ORCID http://orcid.org/0000-0002-8338-1739
Maud Kamal *Department of Drug Development and Innovation (D3i), Institut Curie, 75005, Paris, France. maud.kamal@gustaveroussy.fr.ORCID http://orcid.org/0000-0003-1466-0950
Laurene SyxBioinformatics and Computational Systems Biology of Cancer, Institut Curie, PSL Research University, Mines Paris Tech, INSERM U900, 75005, Paris, France.ORCID http://orcid.org/0009-0005-5749-0738
Remy NicolleUniversité Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-, 75018, Paris, France.ORCID http://orcid.org/0000-0001-8084-1173
Celia DupainDepartment of Drug Development and Innovation (D3i), Institut Curie, 75005, Paris, France.
Naoual MenssouriINSERM 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Igor DuquesneINSERM 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Pernelle LavaudINSERM 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Claudio NicotraGustave Roussy, DITEP, Gustave Roussy, Villejuif, France.
Maud NgocamusGustave Roussy, DITEP, Gustave Roussy, Villejuif, France.
Ludovic LacroixBiopath department, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0003-2535-1010
Lambros TselikasDepartment of interventional radiology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-8878-4916
Gilles CrehangeDepartment of Radiothérapie, Institut Curie, 75005 Paris & 92210 Saint-Cloud, Paris, France.
Luc FribouletINSERM 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-1129-4978
Zahra Castel-AjgalDepartment of Drug Development and Innovation (D3i), Institut Curie, 75005, Paris, France.
Yann NeuzilletDepartment of Urology, Foch Hospital, Suresnes, France.ORCID http://orcid.org/0000-0003-4345-3598
Edith BorcomanDepartment of Drug Development and Innovation (D3i), Institut Curie, 75005, Paris, France.
Philippe BeuzebocDepartment of Urology, Foch Hospital, Suresnes, France.
Grégoire MarretDepartment of Drug Development and Innovation (D3i), Institut Curie, 75005, Paris, France.
Tom GutmanBioinformatics and Computational Systems Biology of Cancer, Institut Curie, PSL Research University, Mines Paris Tech, INSERM U900, 75005, Paris, France.
Jennifer WongDepartment of Genetics, Institut Curie, 75005, Paris, France.
Francois RadvanyiUMR144, Institut Curie, 75005, Paris, France.ORCID http://orcid.org/0000-0002-5696-6424
Sylvain DureauBiometry unit, direction of clinical research, Institut Curie, 75005, Paris, France.
Jean-Yves ScoazecINSERM 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0003-1604-6823
Nicolas ServantBioinformatics and Computational Systems Biology of Cancer, Institut Curie, PSL Research University, Mines Paris Tech, INSERM U900, 75005, Paris, France.ORCID http://orcid.org/0000-0003-1678-7410
Yves AlloryDepartment of Pathology, Institut Curie, PSL Research University, 75005, Paris, France.ORCID http://orcid.org/0000-0002-5526-077X
Benjamin BesseINSERM 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0001-5090-8189
Fabrice AndreINSERM 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0001-5795-8357
Christophe Le TourneauDepartment of Drug Development and Innovation (D3i), Institut Curie, 75005, Paris, France.ORCID http://orcid.org/0000-0001-9772-4686
Christophe MassardGustave Roussy, DITEP, Gustave Roussy, Villejuif, France.
Ivan BiecheDepartment of Genetics, Institut Curie, 75005, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39478018
PMCPMC11526129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.